[Federal Register Volume 61, Number 102 (Friday, May 24, 1996)]
[Notices]
[Pages 26187-26188]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 96-13105]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
Advisory Committee; Notice of Meeting
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: This notice announces a forthcoming meeting of a public
advisory committee of the Food and Drug Administration (FDA). This
notice also summarizes the procedures for the meeting and methods by
which interested persons may participate in open public hearings before
FDA's advisory committees.
FDA has established an Advisory Committee Information Hotline (the
hotline) using a voice-mail telephone system. The hotline provides the
public with access to the most current information on FDA advisory
committee meetings. The advisory committee hotline, which will
disseminate current
[[Page 26188]]
information and information updates, can be accessed by dialing 1-800-
741-8138 or 301-443-0572. Each advisory committee is assigned a 5-digit
number. This 5-digit number will appear in each individual notice of
meeting. The hotline will enable the public to obtain information about
a particular advisory committee by using the committee's 5-digit
number. Information in the hotline is preliminary and may change before
a meeting is actually held. The hotline will be updated when such
changes are made.
MEETING: The following advisory committee meeting is announced:
Science Board to the Food and Drug Administration
Date, time, and place. June 13, 1996, 8:30 a.m., Sheraton--Crystal
City, Ballroom A, 1800 Jefferson Davis Hwy., Arlington, VA.
Type of meeting and contact person. Open committee discussion, 8:30
a.m. to 2:30 p.m.; open public hearing, 2:30 p.m. to 3:30 p.m., unless
public participation does not last that long; open committee
discussion, 3:30 p.m. to 5 p.m.; Susan Homire, Office of Science (HF-
33), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD
20857, 301-827-3340, or FDA Advisory Committee Information Hotline, 1-
800-741-8138 (301-443-0572 in the Washington, DC area), Science Board
to the Food and Drug Administration, code 12603. Please call the
hotline for information concerning any possible changes.
General function of the board. The board shall provide advice
primarily to the agency's Senior Science Advisor, and, as needed, to
the Commissioner and other appropriate officials on specific complex
and technical issues as well as emerging issues within the scientific
community in industry and academia. Additionally, the board will
provide advice to the agency on keeping pace with technical and
scientific evolutions in the fields of regulatory science; on
formulating an appropriate research agenda; and on upgrading its
scientific and research facilities to keep pace with these changes. It
will also provide the means for critical review of agency-sponsored
intramural and extramural scientific research programs.
Agenda--Open public hearing. Interested persons may present data,
information, or views, orally or in writing, on issues pending before
the board. Those desiring to make formal presentations must notify the
contact person before June 6, 1996, and submit a brief statement of the
general nature of the evidence or arguments they wish to present, and
the names and addresses of proposed participants. Each presenter will
be limited in time and not all requests to speak may be able to be
accommodated. All written statements submitted in a timely fashion will
be provided to the board.
Open board discussion. The board will continue its discussions
related to FDA's approach to toxicity, carcinogenicity and biomaterials
testing.
FDA public advisory committee meetings may have as many as four
separable portions: (1) An open public hearing, (2) an open committee
discussion, (3) a closed presentation of data, and (4) a closed
committee deliberation. Every advisory committee meeting shall have an
open public hearing portion. Whether or not it also includes any of the
other three portions will depend upon the specific meeting involved.
There are no closed portions for the meetings announced in this notice.
The dates and times reserved for the open portions of each committee
meeting are listed above.
The open public hearing portion of each meeting shall be at least 1
hour long unless public participation does not last that long. It is
emphasized, however, that the 1 hour time limit for an open public
hearing represents a minimum rather than a maximum time for public
participation, and an open public hearing may last for whatever longer
period the committee chairperson determines will facilitate the
committee's work.
Public hearings are subject to FDA's guideline (subpart C of 21 CFR
part 10) concerning the policy and procedures for electronic media
coverage of FDA's public administrative proceedings, including hearings
before public advisory committees under 21 CFR part 14. Under 21 CFR
10.205, representatives of the electronic media may be permitted,
subject to certain limitations, to videotape, film, or otherwise record
FDA's public administrative proceedings, including presentations by
participants.
Meetings of advisory committees shall be conducted, insofar as is
practical, in accordance with the agenda published in this Federal
Register notice. Changes in the agenda will be announced at the
beginning of the open portion of a meeting.
Any interested person who wishes to be assured of the right to make
an oral presentation at the open public hearing portion of a meeting
shall inform the contact person listed above, either orally or in
writing, prior to the meeting. Any person attending the hearing who
does not in advance of the meeting request an opportunity to speak will
be allowed to make an oral presentation at the hearing's conclusion, if
time permits, at the chairperson's discretion.
The agenda, the questions to be addressed by the committee, and a
current list of committee members will be available at the meeting
location on the day of the meeting.
Transcripts of the open portion of the meeting may be requested in
writing from the Freedom of Information Office (HFI-35), Food and Drug
Administration, rm. 12A-16, 5600 Fishers Lane, Rockville, MD 20857,
approximately 15 working days after the meeting, at a cost of 10 cents
per page. The transcript may be viewed at the Dockets Management Branch
(HFA-305), Food and Drug Administration, rm. 1-23, 12420 Parklawn Dr.,
Rockville, MD 20857, approximately 15 working days after the meeting,
between the hours of 9 a.m. and 4 p.m., Monday through Friday. Summary
minutes of the open portion of the meeting may be requested in writing
from the Freedom of Information Office (address above) beginning
approximately 90 days after the meeting.
This notice is issued under section 10(a)(1) and (2) of the Federal
Advisory Committee Act (5 U.S.C. app. 2), and FDA's regulations (21 CFR
part 14) on advisory committees.
Dated: May 20, 1996.
Michael A. Friedman,
Deputy Commissioner for Operations.
[FR Doc. 96-13105 Filed 5-23-96; 8:45 am]
BILLING CODE 4160-01-F
